

# NOTIFY

Suffolk, ss.

COMMONWEALTH OF MASSACHUSETTS,

Plaintiff,

v.

ALLERGAN LIMITED; ALLERGAN FINANCE,  
LLC; WATSON LABORATORIES, INC.; ACTAVIS  
PHARMA, INC.; ACTAVIS LLC; TEVA  
PHARMACEUTICAL INDUSTRIES, LTD.; TEVA  
PHARMACEUTICALS USA, INC.; AND  
CEPHALON, INC.,

Defendants.

SUPERIOR COURT

C.A. NO. 23-2787F

## **FINAL CONSENT JUDGMENT AS TO THE ALLERGAN DEFENDANTS PURSUANT TO RULE 54(b)**

The Commonwealth of Massachusetts (“*Commonwealth*”) and Allergan Limited (f/k/a Allergan plc, which, in turn, was f/k/a Actavis plc), and Allergan Finance, LLC (f/k/a Actavis, Inc., which, in turn was f/k/a Watson Pharmaceuticals, Inc.)(the latter two collectively, “*Allergan*” or “*Allergan Defendants*”) (together with the Commonwealth, the “*Parties*,” and each a “*Party*”) have entered into a consensual resolution of the above-captioned litigation (the “*Action*”), pursuant to a settlement agreement entitled Allergan Public Global Opioid Settlement Agreement, dated as of November 22, 2022 (as subsequently updated) (the “*Agreement*”), a copy of which is attached hereto as Exhibit A.<sup>1</sup> The Agreement shall become effective by its terms upon the entry of this Final Consent Judgment (the “*Judgment*”) by the Court without trial or adjudication of any contested issue of fact or law, and without finding or admission of wrongdoing or liability of any

<sup>1</sup> Pages of exhibits C, G, and I to the Agreement that relate to states other than Massachusetts have been removed to streamline this filing. A complete copy of the Agreement is available at <https://nationalopioidsettlement.com/>.

JUDGMENT ENTERED ON DOCKET 12/11 20 23  
PURSUANT TO THE PROVISIONS OF MASS. R. CIV. P. 58(a)  
AND NOTICE-SEND TO PARTIES PURSUANT TO THE PRO-  
VISIONS OF MASS. R. CIV. P. 77(d) AS FOLLOWS

kind. This Consent Judgment resolves litigation as to “Allergan” and the “Released Entities” as those terms are defined in the Allergan Public Global Opioid Settlement Agreement.

**RECITALS:**

1. Each Party warrants and represents that it engaged in arm’s-length negotiations in good faith. By entering into the Agreement, the Parties intended to effect a good-faith settlement.

2. The Commonwealth has determined that the Agreement is in the public interest.

3. Allergan denies the allegations in the Action and maintains that it has no liability whatsoever to the Commonwealth, its Subdivisions, its Special Districts and/or any other governmental entity (whether or not such governmental entity has brought or is a party to an Action or not).

4. The Parties have agreed to the resolution of the Action and the entry of this Judgment (including the injunctive terms incorporated herein) by the Court without trial or finding of admission or wrongdoing or liability of any kind.

5. The Parties recognize that the outcome of the Action is uncertain and a final resolution through the adversarial process likely will require protracted litigation.

6. Allergan is entering into this Judgment solely for the purpose of settlement, and nothing contained herein may be taken as or construed to be an admission or concession of any violation of law, rule, regulation, or ordinance, or of any other matter of fact or law, or of any fault, liability, or wrongdoing, all of which Allergan denies.

7. The Parties agree to the entry of the injunctive relief terms pursuant to Exhibit P of the Agreement.

8. Therefore, without any admission of liability or wrongdoing by Allergan or any other Released Entities (as defined in the Agreement), the Parties now mutually consent to the

entry of this Judgment pursuant to the terms of the Agreement to avoid the delay, expense, inconvenience, and uncertainty of protracted litigation.

**NOW THEREFORE, IT IS HEREBY ORDERED, ADJUDGED AND DECREED THAT:**

There being no just reason for delay, and in consideration of the mutual promises, terms, and conditions set forth in the Agreement, the adequacy of which is hereby acknowledged by all Parties, it is agreed by and between the Allergan Defendants and the Commonwealth, and adjudicated by the Court, as follows:

1. The foregoing Recitals are incorporated herein and constitute an express term of this Judgment.
2. The Parties have entered into a full and final settlement of all Released Claims of Releasers (including but not limited to the Commonwealth) against Allergan and the Released Entities pursuant to the terms and conditions set forth in the Agreement.
3. The "Definitions" set forth in Section I of the Agreement are incorporated by reference into this Judgment. The Commonwealth is a "Settling State" within the meaning of the Agreement. Unless otherwise defined herein, capitalized terms in this Judgment shall have the same meaning given to them in the Agreement. In the event of a conflict between the terms of the Agreement and this Judgment, the terms of the Agreement shall govern.
4. The Parties agree that the Court has jurisdiction over the subject matter of the Action and over the Parties with respect to the Action and this Judgment. This Judgment shall not be construed or used as a waiver of any jurisdictional defense Allergan or any other Released Entity may raise in any other proceeding.
5. The Court finds that the Agreement was entered into in good faith.
6. The Court finds that entry of this Judgment is in the public interest and reflects a negotiated settlement agreed to by the Parties. The Action with respect to the Allergan Defendants,

Allergan Limited and Allergan Finance, LLC, is resolved fully and finally by entry of this Judgment pursuant to Rule 54(b), Massachusetts Rules of Civil Procedure. A separate Consent Judgment entered into by the Commonwealth and Teva Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., Cephalon, Inc., Watson Laboratories, Inc., Actavis Pharma, Inc., and Actavis LLC (the "Teva Defendants"), upon entry by the Court, resolves the Action with respect to the remaining defendants in this Action. The Action is fully and finally resolved with respect to the Allegan Defendants and the Teva Defendants upon the entry of the respective Consent Judgments, which shall have the effect of dismissing the Action with prejudice, subject to a retention of jurisdiction by the Court as provided herein and in the Agreement.

7. By this Judgment, the Agreement is hereby approved by the Court, and the Court hereby adopts the Agreement's terms as its own determination of this matter and the Parties' respective rights and obligations.

8. The Court shall have authority to resolve disputes identified in Section XIV.G.2 of the Agreement, governed by the rules and procedures of the Court.

9. Payments. Allergan shall pay the Global Settlement Abatement Amounts and Additional Restitution allocable to Massachusetts in accordance with the Agreement. Global Settlement Abatement Amounts shall be allocated and utilized in accordance with the Massachusetts State-Subdivision Agreement, a copy of which is attached hereto as Exhibit B and incorporated herein by reference. For avoidance of doubt, only Subdivisions that have accepted the terms of the Agreement, including the releases provided therein, shall be eligible to receive Global Settlement Abatement Amounts. Additional Restitution shall be allocated: 60% to the Opioid Recovery and Remediation Trust Fund established pursuant to M.G.L. c. 10, §35000 to mitigate the impacts of the opioid epidemic in the Commonwealth; and 40% to an account held by

TRUE COPY OF JUDGEMENT DULY ENTERED ON 12/11/23

the Office of the Attorney General, pursuant to G.L. c. 12 § 4A, to be used in the Attorney General's sole discretion to support efforts to enforce compliance with state and federal laws and regulations that protect Massachusetts health care consumers or otherwise support initiatives to assist Massachusetts health care consumers and programs. Nothing in this paragraph shall be interpreted to be inconsistent with the Agreement.

10. Injunctive Relief. Allergan shall implement the injunctive relief set forth in Exhibit P to the Agreement and incorporated into this Judgment as if fully set forth herein, in accordance with the Agreement.

11. The Parties have satisfied the Condition to Effectiveness of Agreement set forth in Section X of the Agreement and the Release set forth in Sections V.A, E and F of the Agreement.

12. Release. The Parties acknowledge that the Release, a copy of which is attached hereto as Exhibit C and incorporated by reference herein, is an integral part of this Judgment. Pursuant to the Agreement and the Release and without limitation and to the maximum extent of the power of the Commonwealth's Attorney General, Allergan and the other Released Entities are, as of the Effective Date, hereby released from any and all Released Claims as provided in the Agreement. Further, the provisions set forth in Section V of the Agreement are incorporated by reference into this Judgment as if fully set forth herein. The Parties acknowledge, and the Court finds, that those provisions are an integral part of the Agreement and this Judgment and shall govern the rights and obligations of all participants in the settlement. Any modification of those rights and obligations may be made based only on a writing signed by all affected parties and approved by the Court.

13. Release of Unknown Claims. The Commonwealth expressly waives, releases, and forever discharges any and all provisions, rights, and benefits conferred by any law of any state or

TRUE COPY OF JUDGEMENT DULY ENTERED ON 12/11/23

territory of the United States or other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to § 1542 of the California Civil Code, which reads:

**General Release; extent.** A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

14. The Commonwealth may hereafter discover facts other than or different from those which it knows, believes, or assumes to be true with respect to the Released Claims, but the Commonwealth expressly waived and fully, finally, and forever settled, released and discharged, through the Agreement and Release, any and all Released Claims that may exist as of the Effective Date but which the Commonwealth does not know or suspect to exist, whether through ignorance, oversight, error, negligence or through no fault whatsoever, and which, if known, would have materially affected the Commonwealth's decision to enter into the Agreement.

15. Costs and Fees. The Parties will bear their own costs and attorneys' fees except as otherwise provided in the Agreement.

16. No Admission of Liability. The Allergan Defendants are consenting to this Judgment solely for the purpose of effectuating the Agreement, and nothing contained herein may be taken as or construed to be an admission or concession of any violation of law, rule, or regulation, or of any other matter of fact or law, or of any liability or wrongdoing, all of which the Allergan Defendants expressly deny. No Defendant or Released Entity admits that it caused or contributed to any public nuisance, and no Defendant or Released Entity admits any wrongdoing that was or could have been alleged by the Commonwealth, its Participating Subdivisions and/or Participating Special Districts, or any other person or entity. No part of this Judgment shall constitute evidence of any liability, fault, or wrongdoing by the Allergan Defendants or any other Released Entity. The Parties acknowledge that payments made under the Agreement are

Compensatory Restitution Amounts and are properly characterized as described in Section VIII.G of the Agreement.

17. No Waiver. This Judgment is entered based on the Agreement without trial or adjudication of any contested issue of fact or law or finding of liability of any kind. This Judgment shall not be construed or used as a waiver of Allergan's right, or any other Released Entity's right, to defend itself from, or make any arguments in, any other regulatory, governmental, private individual, or class claims or suits relating to the subject matter or terms of this Judgment. Notwithstanding the foregoing, the Commonwealth may enforce the terms of this Judgment as expressly provided in the Agreement.

18. No Private Right of Action. No part of this Judgment or of the Agreement shall create a private cause of action or confer any right to any third party for violation of any federal or state statute. This Judgment is not intended for use by any third party for any purpose, including submission to any court for any purpose, except pursuant to Section XIV.A of the Agreement. Except as expressly provided in the Agreement, no portion of the Agreement or this Judgment shall provide any rights to, or be enforceable by, any person or entity that is not a Settling State or Released Entity. The Commonwealth shall allow Participating Subdivisions and Participating Special Districts in the Commonwealth to notify it of any perceived violations of the Agreement or this Judgment. No Settling State, including the Commonwealth, may assign or otherwise convey any right to enforce any provision of the Agreement.

19. Admissibility. It is the intent of the Parties that this Judgment not be admissible in other cases against the Allergan Defendants or Released Entities or binding on the Allergan Defendants or Released Entities in any respect other than in connection with the enforcement of this Judgment or the Agreement. For the avoidance of doubt, nothing herein shall prohibit the

TRUE COPY OF JUDGEMENT DULY ENTERED ON 12/11/23

Allergan Defendants or Released Entities from entering this Judgment or the Agreement into evidence in any litigation or arbitration concerning (1) the Allergan Defendants' or Released Entities' right to coverage under an insurance contract or (2) the enforcement of the releases provided for by the Agreement and this Judgment.

20. Preservation of Privilege. Nothing contained in the Agreement or this Judgment, and no act required to be performed pursuant to the Agreement or this Judgment, is intended to constitute, cause, or effect any waiver (in whole or in part) of any attorney-client privilege, work product protection, or common interest/joint defense privilege, and each Party agrees that it shall not make or cause to be made in any forum any assertion to the contrary.

21. Mutual Interpretation. The Parties agree and stipulate that the Agreement was negotiated on an arm's-length basis between parties of equal bargaining power and was drafted jointly by counsel for each Party. Accordingly, the Agreement is incorporated herein by reference and shall be mutually interpreted and not construed in favor of or against any Party, except as expressly provided for in the Agreement.

22. Retention of Jurisdiction. The Court shall retain jurisdiction of the Parties for the limited purpose of the resolution of disputes identified in Section XIV.G.2 of the Agreement. The Court shall have jurisdiction over Participating Subdivisions and Participating Special Districts in the Commonwealth for the limited purposes identified in the Agreement.

23. Successors and Assigns. This Judgment is binding on the Allergan Defendants' successors and assigns.

24. Modification. Neither the Agreement, any exhibit or form attached thereto, nor this Judgment shall be modified (by the Court, by any other court, or by any other means) without the

TRUE COPY OF JUDGEMENT DULY ENTERED ON 12/11/23



consent of the Commonwealth and the Allergan Defendants, or as provided for in Section XVI.T  
of the Agreement.

So ORDERED this 8 day of December, 2023.

Enter:

12.8.23

By Order:

[Signature]

Michael L. Doolittle

~~TRUE COPY OF JUDGEMENT DULY ENTERED ON 12/11/23~~

**APPROVED, AGREED TO AND PRESENTED BY:**

*Richard M. Zielinski*

Richard M. Zielinski (BBO No. 540060)  
GOULSLSTOTON & STOTORRS PC  
400 Atlantntic Avevenue  
Boston, MA 021 21 10 10-3333  
TeTelephone: (617) 482-17176  
rzeilinski@g@gououlststonst ororr.s.comom

Date: November 21, 2023

**Counsel for the Allergan Defendants**

Gregory  
Hardy

Digitally signed by  
Gregory Hardy  
Date: 2023.11.28  
14:41:04 -05'00'

Gregory A. Hardy (BBO #705433)  
Assistant Attorney General  
Health Care Division  
Office of the Attorney General  
One Ashburton Place  
Boston, MA 02108  
Telephone: (617) 963-2353  
Gregory.Hardy@mass.gov

Dated: November 28, 2023

**Counsel for the Commonwealth of Massachusetts**

TRUE COPY OF JUDGEMENT DULY ENTERED ON 12/11/23